Summary of Key Points Core Viewpoint - Nanjing Qianjing plans to reduce its holdings in Guangzhou Anbiping Pharmaceutical Technology Co., Ltd. due to funding needs, with a total reduction not exceeding 1,677,265 shares, representing 1.79% of the company's total share capital [2][5]. Shareholder Holding Situation - As of the announcement date, Nanjing Qianjing holds 1,677,265 shares, accounting for 1.79% of the total share capital, which were acquired before the company's IPO and became tradable after August 20, 2021 [2][3]. Reduction Plan Details - Nanjing Qianjing intends to reduce its holdings through two methods: - A maximum of 935,676 shares (1.00% of total share capital) via centralized bidding - A maximum of 741,589 shares (0.79% of total share capital) through block trading - The reduction will take place within three months starting 15 trading days after the announcement [2][4]. Compliance and Commitments - Nanjing Qianjing has made commitments regarding its shareholding, including: - Adhering to lock-up agreements for shares held before the IPO - Ensuring that any reduction in shares within two years post-lock-up will not be below the issue price, adjusted for any corporate actions [3][4]. - The company will comply with relevant laws and regulations regarding share reductions and will disclose plans in advance [5].

Group 1 - The core announcement states that Nanjing Qianjing Venture Capital Partnership holds approximately 1.68 million shares of Guangzhou Anbiping Pharmaceutical Technology Co., Ltd., accounting for 1.79% of the company's total share capital [2] - Nanjing Qianjing plans to reduce its holdings through centralized bidding and block trading, with a maximum reduction of approximately 1.68 million shares, which is 1.79% of the total share capital [2] - The planned reduction includes up to approximately 940,000 shares through centralized bidding (1% of total share capital) and up to approximately 740,000 shares through block trading (0.79% of total share capital) [2]

证券代码：688393 证券简称：安必平 公告编号：2025-033 广州安必平医药科技股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 股东持有的基本情况 截至本公告披露日，南京乾靖创业投资合伙企业（有限合伙）（以下简称"南 京乾靖"）持有广州安必平医药科技股份有限公司（以下简称"公司"）1,677,265 股股份，占公司总股本的比例为 1.79%，该等股份为南京乾靖于公司首次公开发 行并上市前取得的股份，且已于 2021 年 8 月 20 日解除限售后上市流通。 减持计划的主要内容 1 根据相关法律、法规的规定及股东承诺，南京乾靖持股低于 5%后，仅通过集中竞价方 式减持需要披露减持计划。 因股东资金需求，南京乾靖拟通过集中竞价方式及大宗交易方式减持所持有 的公司股份不超过 1,677,265 股(含本数)，不超过公司目前总股本的 1.79%。其 中，通过集中竞价方式减持股份不超过 935,676 股(含本数)，不超过公司目前总 股本的 1.00%；通过大宗 ...

人民财讯8月13日电，安必平(688393)8月13日晚间公告，公司持股1.79%的股东南京乾靖创业投资合伙 企业(有限合伙)(简称"南京乾靖")拟通过集中竞价及大宗交易方式，减持公司股份不超过167.73万股 (含)，即不超过公司目前总股本的1.79%。 ...

格隆汇8月13日丨安必平(688393.SH)公布，因股东资金需求，南京乾靖拟通过集中竞价方式及大宗交易 方式减持所持有的公司股份不超过167.73万股(含本数)，不超过公司目前总股本的1.79%。其中，通过集 中竞价方式减持股份不超过93.57万股(含本数)，不超过公司目前总股本的1.00%；通过大宗交易方式减 持股份不超过74.16万股(含本数)，不超过公司目前总股本的0.79%，上述减持自本公告披露之日起15个 交易日之后的3个月内进行。 ...

8月13日，医疗器械行业上涨0.09%，今日主力资金流出7.93亿元，成分股40只上涨，57只下跌。 主力资金净流出居前的分别为安必平（1959.61万元）、美好医疗（1874.35万元）、ST凯利（1873.81万 元）、超研股份（1867.59万元）、万孚生物（1671.12万元）。 序号代码名称最新价涨跌幅主力净流入主力净占比1688108赛诺医疗29.517.481.19亿元3.43%2300289利 德曼11.334.916644.74万元4.8%3870199倍益康47.346.533963.65万元10.19%4688068热景生物 232.611.413236.01万元5.98%5300238冠昊生物18.283.753164.59万元8.39%6688277天智航- U19.232.181872.46万元7.35%7002022科华生物7.742.111469.12万元6.4%8603987康德莱9.340.971360.65 万元4.53%9688271联影医疗131.04-0.11182.31万元2.08%10300653正海生物22.58-0.881148.09万元8.24% 来源：金 ...

Core Viewpoint - The article highlights the increasing instances of illegal share reductions by major shareholders in listed companies, emphasizing the need for stricter regulations to restore investor confidence and maintain market integrity [1][5]. Group 1: Instances of Illegal Share Reductions - Over 60 listed companies have announced illegal share reductions by shareholders this year, with violations including breach of commitments and failure to disclose [1]. - Notable cases include shareholders of Anbiping and Jiuliang Co. engaging in illegal reductions due to calculation errors and failure to disclose plans, amounting to approximately 28.77 million yuan and 2.009 million yuan respectively [2][3]. - The case of Guo Zilong from Jiuliang Co. is highlighted, where he reduced shares below the IPO price, violating his commitment [3]. Group 2: Regulatory Response - Regulatory bodies have intensified their crackdown on illegal share reductions, with over 50 companies facing penalties or regulatory actions this year [5][6]. - A logistics company's controlling shareholder was publicly reprimanded for failing to disclose a reduction plan, having sold 53.18 million shares, amounting to 264 million yuan [6]. - The Shenzhen Stock Exchange imposed trading restrictions on shareholders involved in illegal reductions, aiming to uphold market order and protect minority investors [7]. Group 3: Motivations Behind Illegal Reductions - Major shareholders often possess information advantages, allowing them to exploit market conditions for profit through illegal reductions [4]. - The potential for significant financial gain serves as a strong motivation for these shareholders to engage in such practices [4]. Group 4: Market Impact - The prevalence of illegal share reductions undermines the image of companies and their management, negatively affecting investor confidence in the secondary market [1][5]. - Stricter regulations are seen as essential for creating a transparent and orderly market environment, which is crucial for attracting long-term investments [7].

Group 1 - The core viewpoint of the news is that Anbiping (688393) has experienced a decline in revenue and profit in its latest quarterly report, indicating potential challenges for the company [1][3] - As of August 11, 2025, Anbiping's stock closed at 31.62 yuan, with a 1.84% increase and a turnover rate of 3.41% [1] - The company's main funds saw a net outflow of 18.39% of the transaction amount, with significant outflows from large orders [1] Group 2 - Anbiping reported total operating revenue of 72.54 million yuan for the first quarter of 2025, a year-on-year decrease of 28.51% [1] - The net profit attributable to the parent company was 11.06 million yuan, down 238.49% year-on-year, while the non-recurring net profit decreased by 370.16% to 12.97 million yuan [1] - The company's liquidity ratios are strong, with a current ratio of 10.333 and a quick ratio of 8.947, while the debt-to-asset ratio stands at 8.25% [1] Group 3 - Anbiping has made investments in 16 companies and participated in 611 bidding projects, indicating active engagement in business development [2] - The company holds 29 trademark registrations and 91 patents, along with 92 administrative licenses, showcasing its focus on intellectual property [2]

Group 1 - The core viewpoint of the article highlights the significant decline in the stock price of Anbiping, which closed at 31.05 yuan, down 6.87%, with a rolling PE ratio of 1298.45 times, indicating a substantial overvaluation compared to the industry average [1] - Anbiping's total market capitalization is reported at 2.905 billion yuan, which is considerably lower than the industry average market capitalization of 11.731 billion yuan [2] - The company operates in the medical device sector, focusing on tumor screening and diagnostic reagents, automation equipment, and AI-assisted diagnostic software [1] Group 2 - As of March 31, 2025, Anbiping has 10,309 shareholders, an increase of 4,393 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - The latest quarterly report for Q1 2025 shows that Anbiping achieved a revenue of 72.5435 million yuan, a year-on-year decrease of 28.51%, and a net loss of approximately 11.064 million yuan, reflecting a year-on-year decline of 238.49% [1] - The company's gross profit margin stands at 61.97%, indicating a relatively high profitability despite the revenue decline [1]

来源：金融界 主力资金净流出居前的分别为安必平（1174.99万元）、东富龙（1070.65万元）、安杰思（995.13万 元）、微电生理（983.9万元）、可孚医疗（916.41万元）。 序号代码名称最新价涨跌幅主力净流入主力净占比1300760迈瑞医疗230.71-0.031.07亿元7.18%2300003 乐普医疗17.276.931.07亿元5.73%3301363美好医疗20.037.175599.57万元11.04%4603987康德莱 9.235.734851.48万元12.43%5870199倍益康42.581.383949.32万元7.52%6002551尚荣医疗4.649.953736.73 万元22.93%7688068热景生物243.022.543614.97万元6.9%8688314康拓医疗40.08.113278.73万元 15.1%9688108赛诺医疗20.4420.022762.62万元19.98%10832278鹿得医疗12.484.962727.93万元13.05% 8月8日，医疗器械行业上涨0.93%，今日主力资金流出6.11亿元，成分股59只上涨，39只下跌。 ...